Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) EBT Margin (2016 - 2025)

Historic EBT Margin for Zevra Therapeutics (ZVRA) over the last 9 years, with Q3 2025 value amounting to 3.74%.

  • Zevra Therapeutics' EBT Margin rose 8942300.0% to 3.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 63.55%, marking a year-over-year increase of 4296100.0%. This contributed to the annual value of 381.76% for FY2024, which is 2140700.0% down from last year.
  • As of Q3 2025, Zevra Therapeutics' EBT Margin stood at 3.74%, which was up 8942300.0% from 296.93% recorded in Q2 2025.
  • Zevra Therapeutics' 5-year EBT Margin high stood at 319.93% for Q4 2022, and its period low was 1904.38% during Q2 2022.
  • Over the past 5 years, Zevra Therapeutics' median EBT Margin value was 103.37% (recorded in 2021), while the average stood at 242.25%.
  • Its EBT Margin has fluctuated over the past 5 years, first tumbled by -19561400bps in 2022, then soared by 18731300bps in 2023.
  • Quarter analysis of 5 years shows Zevra Therapeutics' EBT Margin stood at 103.37% in 2021, then surged by 410bps to 319.93% in 2022, then crashed by -148bps to 153.96% in 2023, then dropped by -10bps to 169.56% in 2024, then surged by 98bps to 3.74% in 2025.
  • Its EBT Margin was 3.74% in Q3 2025, compared to 296.93% in Q2 2025 and 9.4% in Q1 2025.